Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.76
CBM's Cash to Debt is ranked higher than
53% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CBM: 0.76 )
CBM' s 10-Year Cash to Debt Range
Min: 0.04   Max: 0.76
Current: 0.76

0.04
0.76
Equity to Asset 0.52
CBM's Equity to Asset is ranked higher than
63% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBM: 0.52 )
CBM' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.57
Current: 0.52

0.22
0.57
F-Score: 7
Z-Score: 5.22
M-Score: -2.36
WACC vs ROIC
14.68%
25.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.96
CBM's Operating margin (%) is ranked higher than
91% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CBM: 13.96 )
CBM' s 10-Year Operating margin (%) Range
Min: -2.77   Max: 18.02
Current: 13.96

-2.77
18.02
Net-margin (%) 15.30
CBM's Net-margin (%) is ranked higher than
92% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CBM: 15.30 )
CBM' s 10-Year Net-margin (%) Range
Min: -98.33   Max: 82.87
Current: 15.3

-98.33
82.87
ROE (%) 25.07
CBM's ROE (%) is ranked higher than
96% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CBM: 25.07 )
CBM' s 10-Year ROE (%) Range
Min: -94.37   Max: 120.02
Current: 25.07

-94.37
120.02
ROA (%) 12.40
CBM's ROA (%) is ranked higher than
95% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CBM: 12.40 )
CBM' s 10-Year ROA (%) Range
Min: -37.93   Max: 42.71
Current: 12.4

-37.93
42.71
ROC (Joel Greenblatt) (%) 20.99
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CBM: 20.99 )
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.31   Max: 32.71
Current: 20.99

-3.31
32.71
Revenue Growth (3Y)(%) 11.00
CBM's Revenue Growth (3Y)(%) is ranked higher than
83% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CBM: 11.00 )
CBM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18   Max: 11
Current: 11

-18
11
EBITDA Growth (3Y)(%) 14.90
CBM's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CBM: 14.90 )
CBM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27   Max: 32.8
Current: 14.9

-27
32.8
EPS Growth (3Y)(%) 58.70
CBM's EPS Growth (3Y)(%) is ranked higher than
97% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CBM: 58.70 )
CBM' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.5   Max: 79.7
Current: 58.7

-21.5
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CBM Guru Trades in Q1 2014

Paul Tudor Jones 18,500 sh (-4.65%)
Jim Simons 470,525 sh (-25.74%)
Chuck Royce 951,854 sh (-37.66%)
» More
Q2 2014

CBM Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
Chuck Royce 801,354 sh (-15.81%)
Jim Simons 328,200 sh (-30.25%)
» More
Q3 2014

CBM Guru Trades in Q3 2014

Chuck Royce 921,629 sh (+15.01%)
Jim Simons 261,500 sh (-20.32%)
» More
Q4 2014

CBM Guru Trades in Q4 2014

Joel Greenblatt 78,575 sh (New)
Paul Tudor Jones 17,728 sh (New)
Chuck Royce 956,112 sh (+3.74%)
Chuck Royce 956,112 sh (unchged)
Jim Simons 154,600 sh (-40.88%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.30
CBM's P/E(ttm) is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 23.30 )
CBM' s 10-Year P/E(ttm) Range
Min: 1.05   Max: 63.2
Current: 23.3

1.05
63.2
Forward P/E 23.98
CBM's Forward P/E is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 23.98 )
N/A
PE(NRI) 22.70
CBM's PE(NRI) is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 22.70 )
CBM' s 10-Year PE(NRI) Range
Min: 5.17   Max: 129.95
Current: 22.7

5.17
129.95
P/B 5.20
CBM's P/B is ranked higher than
68% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CBM: 5.20 )
CBM' s 10-Year P/B Range
Min: 0.61   Max: 5.33
Current: 5.2

0.61
5.33
P/S 3.63
CBM's P/S is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CBM: 3.63 )
CBM' s 10-Year P/S Range
Min: 0.18   Max: 10.71
Current: 3.63

0.18
10.71
PFCF 32.70
CBM's PFCF is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 32.70 )
CBM' s 10-Year PFCF Range
Min: 4.81   Max: 245.33
Current: 32.7

4.81
245.33
POCF 20.33
CBM's POCF is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 20.33 )
CBM' s 10-Year POCF Range
Min: 2.94   Max: 65
Current: 20.33

2.94
65
EV-to-EBIT 24.95
CBM's EV-to-EBIT is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 24.95 )
CBM' s 10-Year EV-to-EBIT Range
Min: -2271   Max: 388.4
Current: 24.95

-2271
388.4
PEG 2.06
CBM's PEG is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 2.06 )
CBM' s 10-Year PEG Range
Min: 0.52   Max: 42.7
Current: 2.06

0.52
42.7
Shiller P/E 44.10
CBM's Shiller P/E is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 44.10 )
CBM' s 10-Year Shiller P/E Range
Min: 5.64   Max: 141.6
Current: 44.1

5.64
141.6
Current Ratio 2.30
CBM's Current Ratio is ranked higher than
60% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CBM: 2.30 )
CBM' s 10-Year Current Ratio Range
Min: 1.72   Max: 3.48
Current: 2.3

1.72
3.48
Quick Ratio 1.44
CBM's Quick Ratio is ranked higher than
57% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CBM: 1.44 )
CBM' s 10-Year Quick Ratio Range
Min: 0.88   Max: 2
Current: 1.44

0.88
2
Days Inventory 139.34
CBM's Days Inventory is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 139.34 )
CBM' s 10-Year Days Inventory Range
Min: 107.67   Max: 228.78
Current: 139.34

107.67
228.78
Days Sales Outstanding 75.14
CBM's Days Sales Outstanding is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CBM: 75.14 )
CBM' s 10-Year Days Sales Outstanding Range
Min: 49.84   Max: 112.79
Current: 75.14

49.84
112.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.70
CBM's Price/Tangible Book is ranked higher than
72% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CBM: 6.70 )
CBM' s 10-Year Price/Tangible Book Range
Min: 2.02   Max: 12.46
Current: 6.7

2.02
12.46
Price/DCF (Projected) 3.30
CBM's Price/DCF (Projected) is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 3.30 )
CBM' s 10-Year Price/DCF (Projected) Range
Min: 1.03   Max: 9.84
Current: 3.3

1.03
9.84
Price/Median PS Value 2.90
CBM's Price/Median PS Value is ranked higher than
68% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CBM: 2.90 )
CBM' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 2.59
Current: 2.9

0.43
2.59
Price/Peter Lynch Fair Value 1.90
CBM's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 1.90 )
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.77   Max: 3.58
Current: 1.9

0.77
3.58
Price/Graham Number 2.60
CBM's Price/Graham Number is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 2.60 )
CBM' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 24.76
Current: 2.6

0.43
24.76
Earnings Yield (Greenblatt) 3.90
CBM's Earnings Yield (Greenblatt) is ranked higher than
93% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CBM: 3.90 )
CBM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 222.1
Current: 3.9

0.3
222.1
Forward Rate of Return (Yacktman) 13.55
CBM's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 15.43 vs. CBM: 13.55 )
CBM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -42.4   Max: 21
Current: 13.55

-42.4
21

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany,
Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Our Partners
AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog Apr 14 2015 - ZACKS

More From Other Websites
NYSE stocks posting largest percentage increases Apr 24 2015
The IBD 50 in an ETF Wrapper Apr 22 2015
New Innovator IBD 50 ETF Makes Strong Debut - ETF News And Commentary Apr 22 2015
Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog Apr 13 2015
5 IBD 50s Offer Triple-Digit Earnings Growth Views Apr 11 2015
Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog Apr 09 2015
Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog Apr 07 2015
Cambrex To Present At The 14th Annual Needham Healthcare Conference Apr 07 2015
Cambrex To Present At The 14th Annual Needham Healthcare Conference Apr 07 2015
The Medicines Co. Settles Angiomax Patent Dispute with Sun - Analyst Blog Apr 02 2015
Stock Indexes Post Gains, But Volume Is Light Apr 02 2015
Stocks Mildly Higher, And CarMax Hits Accelerator Apr 02 2015
Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog Apr 01 2015
Will Cambrex (CBM) Continue to Surge Higher? - Tale of the Tape Apr 01 2015
Cambrex (CBM) Looks Good: Stock Adds 11.6% in Session - Tale of the Tape Apr 01 2015
Cambrex Surges On Analyst Rating; GrubHub Turns Tail Mar 31 2015
BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog Mar 31 2015
Window Dressing Hits Stocks In Final-Hour Sell-Off Mar 31 2015
Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog Mar 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK